Pasithea Therapeutics Appoints Experienced CMO, Grants Substantial Equity Options to Executives and Directors

summarizeSummary

Pasithea Therapeutics appointed Dr. Kartik Krishnan as Chief Medical Officer, a strategic move for its clinical-stage pipeline, accompanied by significant stock option grants to executives and directors.

check_boxKey Events

• Chief Medical Officer Appointed

  Dr. Kartik Krishnan, M.D., Ph.D., was appointed Chief Medical Officer, effective May 1, 2026. He will oversee clinical development and medical strategy for PAS-004, particularly for neurofibromatosis type 1 (NF1).

• Extensive Industry Experience

  Dr. Krishnan has over 20 years of experience, including roles as CEO at OncoNano Medicines and CMO at Arcus Biosciences. His prior work at Genentech on the FDA-approved MEK inhibitor cobimetinib is directly relevant to Pasithea's lead candidate.

• Executive Compensation Details

  Dr. Krishnan's employment agreement includes an initial annual base salary of $500,000 and eligibility for an annual discretionary bonus of up to 40% of his base salary.

• Significant Stock Option Grants

  The Board approved stock option awards for 5,865,170 shares of common stock to executive officers (including Dr. Krishnan, CEO Tiago Reis Marques, and Daniel Schneiderman), certain employees, and non-employee directors. The exercise price for all options is $0.841 per share, the closing price on May 1, 2026.

auto_awesomeAnalysis

Pasithea Therapeutics, a clinical-stage biotechnology company, has appointed Dr. Kartik Krishnan as its Chief Medical Officer. Dr. Krishnan brings over 20 years of experience in clinical development, including work on an FDA-approved MEK inhibitor, which is highly relevant to Pasithea's lead candidate, PAS-004, for neurofibromatosis type 1 (NF1). This appointment is a significant positive for the company's clinical strategy and its ability to advance PAS-004. In connection with this, the company granted substantial stock options to Dr. Krishnan, the CEO, CFO, other employees, and non-employee directors. While these grants represent significant potential future dilution, they are a necessary component of attracting and retaining key talent critical for a clinical-stage biotech's success.